Who is sponsoring NCT03296670?

NCT03296670 is sponsored by RenJi Hospital.

What drugs are being tested in NCT03296670?

Interventions in NCT03296670: Alprostadil, Nitroglycerin.

What condition does NCT03296670 study?

NCT03296670 studies ST Segment Elevation Myocardial Infarction, Coronary Slow Flow Phenomenon.

Is NCT03296670 still recruiting?

NCT03296670 is currently completed. Last updated 12 March 2020.

Last reviewed 2020-03-12 · How we verify

NCT03296670

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients With CSFP

Completed Phase 4 Last updated 12 March 2020

What this trial tests

Phase 4 trial testing Alprostadil in ST Segment Elevation Myocardial Infarction in 57 participants. Completed in 31 August 2017.

Timeline

1 August 2015

Primary endpoint
28 April 2017

31 August 2017

Quick facts

Lead sponsor	RenJi Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	57
Start date	1 August 2015
Primary completion	28 April 2017
Estimated completion	31 August 2017
Sites	1 location across China

Drugs / interventions tested

Alprostadil (ALPROSTADIL) — full drug profile →
Nitroglycerin (glyceryl trinitrate) — full drug profile →

Conditions studied

ST Segment Elevation Myocardial Infarction — all drugs for ST Segment Elevation Myocardial Infarction →
Coronary Slow Flow Phenomenon — all drugs for Coronary Slow Flow Phenomenon →

Sponsor

RenJi Hospital

Who can join

Eligibility, any sex, with ST Segment Elevation Myocardial Infarction or Coronary Slow Flow Phenomenon. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study intends to evaluate the efficacy of different medicine delivering by targeted perfusion catheter in coronary administration on coronary blood flow in STEMI patients with CSFP.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Intracoronary infusion of alprostadil and nitroglycerin with targeted perfusion microcatheter in STEMI patients with coronary slow flow phenomenon.
Sheng X, Ding S, Ge H, Sun Y, et al · · 2018 · cited 16× · PMID 29728334 · DOI 10.1016/j.ijcard.2018.04.119

Verify or expand the search:

Other trials of Alprostadil

Trials testing the same drug.

NCT03252626 — Study on the Efficacy of Alprostadil Injection in Patients With Acute Ischemic Stroke · Phase 4 · unknown
NCT04312555 — Alprostadil as an Adjuvant Therapy With Indirect Angiosomal Revascularization in Critical Limb Ischemia. · Phase 4 · unknown
NCT03892447 — The Comparative Effectiveness of Alprostadil,Sodium Ferulate and Dopamine in Pediatric Acute Kidney Injury · Phase 4 · unknown
NCT03252665 — Efficacy of Intracoronary Infusion of Different Medicine in STEMI Patients Undergoing Primary PCI · Phase 4 · unknown
NCT03027219 — Blood Flow Change After Free Flap Surgery in Diabetic Patients · completed

Other recruiting trials for ST Segment Elevation Myocardial Infarction

Currently open trials in the same condition.

NCT03787745 — Ischemic Postconditioning in STEMI Patients Treated With Primary PCI · NA · recruiting

Other RenJi Hospital trials

Trials by the same sponsor.

NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03296670 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
Last refreshed: 12 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03296670.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing